November 27, 2023 — Truly, access to care for obesity is a tough slog. Not that it’s easy for any health condition. Obesity really is a special case, where medical care that can improve a person’s health often lies just out of reach. Bias about obesity is part of the problem. Fear of mounting medical costs is another. But […]
November 25, 2023 — Two weeks ago, a shift started in the public messaging about semaglutide supply issues that have dogged Novo Nordisk from the very beginning of launching a version of this drug (Wegovy) for obesity. Has the catch-up game in production capacity for obesity and diabetes medicines begun at last in earnest? At the beginning of November, […]
November 17, 2023 — It’s not easy. Getting access to good obesity care and maintaining it is a challenge that is especially frustrating as we see that the options for care are improving. But it seems that health systems right now are rigged to interrupt obesity treatment. An illustration of this comes from a recent study published in Obesity. […]
November 16, 2023 — It was an amazing moment. Hundreds upon hundreds people packed into huge convention hall to hear about the detailed outcomes of the first ever randomized controlled trial to show that treating obesity could prevent heart attacks, strokes, and cardiovascular deaths. The implications of the SELECT trial for obesity care will be enormous and we had […]
November 9, 2023 — In an era of tremendous change for obesity care, this is certainly a huge milestone. FDA approved tirzepatide for obesity treatment yesterday and put Lilly in the position to offer serious competition to Novo Nordisk. But the question that matters most to us is simple. How will this competition help people seeking to cope with […]
October 28, 2023 — Oh my goodness. Wall Street is having waves of panic about the possibility that big food, big burrito, or big dialysis might not be able to keep selling us ever more of their services and stuff. For the last month we’ve been seeing ripples run through the stock market when investors started thinking maybe consumers […]
October 24, 2023 — We have grown tired of the mindless repetition of a $1,350 monthly list price for Wegovy in endless news reports about the great expense of this very important new drug for obesity. Not because the drug isn’t expensive. But because that list price is not an accurate representation of what the drug really costs. So […]
October 19, 2023 — The week that was OW2023 is history now, leaving us to reflect on what we will remember from this gathering of the top minds in obesity science, clinical care, and health policy. The meeting comes at a pivotal time for obesity care, so we have much to learn from the people who came together here. […]
October 16, 2023 — Forgive us a bit of skepticism please. We are facing a jarring disconnect at ObesityWeek from the reality of medical care that simply can’t keep up with stunning progress in obesity science. Scientists and obesity medicine experts are promising us a tantalizing future for obesity care while the present circumstances facing real people living with […]
October 7, 2023 — We have mixed feelings about a new report in JAMA this week about GLP-1 agonists and the associated risk of gastrointestinal adverse events. On one hand, this is helpful data. It is a reminder that despite all of the sensational reporting about “weight loss miracles,” these drugs are serious medicines that require careful prescribing and […]
